{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T15:40:25Z","timestamp":1783698025995,"version":"3.55.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,3,24]],"date-time":"2022-03-24T00:00:00Z","timestamp":1648080000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,24]],"date-time":"2022-03-24T00:00:00Z","timestamp":1648080000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100008484","name":"BioMarin Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008484","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Mucopolysaccharidoses (MPS) are a group of lysosomal storage disorders caused by defects in genes coding for different lysosomal enzymes which degrade glycosaminoglycans. Impaired lysosomal degradation causes cell dysfunction leading to progressive multiorgan involvement, disabling consequences and poor life expectancy. Enzyme replacement therapy (ERT) is now available for most MPS types, offering beneficial effects on disease progression and improving quality of life of patients. The landscape of MPS in Europe is not completely described and studies on availability of treatment show that ERT is not adequately implemented, particularly in Southern and Eastern Europe. In this study we performed a survey analysis in main specialist centers in Southern and Eastern European countries, to outline the picture of disease management in the region and understand ERT implementation. Since the considerable number of MPS IVA patients in the region, particularly adults, the study mainly focused on MPS IVA management and treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>19 experts from 14 Southern and Eastern European countries in total responded to the survey. Results outlined a picture of MPS management in the region, with a high number of MPS patients managed in the centers and a high level of care. MPS II was the most prevalent followed by MPS IVA, with a particular high number of adult patients. The study particularly focused on management and treatment of MPS IVA patients. Adherence to current European Guidelines for follow-up of MPS IVA patients is generally adequate, although some important assessments are reported as difficult due to the lack of MPS skilled specialists. Availability of ERT in Southern and Eastern European countries is generally in line with other European regions, even though regulatory, organizational and reimbursement constrains are demanding.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The landscape of MPS in Southern and Eastern European countries is generally comparable to that of other European regions, regarding epidemiology, treatment accessibility and follow up difficulties. However, issues limiting ERT availability and reimbursement should be simplified, to start treatment as early as possible and make it available for more patients. Besides, educational programs dedicated to specialists should be implemented, particularly for pediatricians, clinical geneticists, surgeons, anesthesiologists and neurologists.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-022-02285-x","type":"journal-article","created":{"date-parts":[[2022,3,24]],"date-time":"2022-03-24T19:02:50Z","timestamp":1648148570000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["The landscape of Mucopolysaccharidosis in Southern and Eastern European countries: a survey from 19 specialistic centers"],"prefix":"10.1186","volume":"17","author":[{"given":"Anna","family":"Tylki-Szyma\u0144ska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zsuzsanna","family":"Alm\u00e1ssy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Violetta","family":"Christophidou-Anastasiadou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Avdjieva-Tzavella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingeborg","family":"Barisic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rimante","family":"Cerkauskiene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Goran","family":"Cuturilo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maja","family":"Djiordjevic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoran","family":"Gucev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Hlavata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beata","family":"Kie\u0107-Wilk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Magner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Pecin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasilica","family":"Plaiasu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mira","family":"Samardzic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Zafeiriou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Zaganas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5529-0506","authenticated-orcid":false,"given":"Christina","family":"Lampe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,24]]},"reference":[{"issue":"Suppl 5","key":"2285_CR1","doi-asserted-by":"crossref","first-page":"v4","DOI":"10.1093\/rheumatology\/ker394","volume":"50","author":"J Muenzer","year":"2011","unstructured":"Muenzer J. Overview of the mucopolysaccharidoses. Rheumatology (Oxford). 2011;50(Suppl 5):v4-12.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"2285_CR2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5582\/irdr.2020.01011","volume":"9","author":"J Zhou","year":"2020","unstructured":"Zhou J, Lin J, Leung WT, Wang L. A basic understanding of mucopolysaccharidosis: incidence, clinical features, diagnosis, and management. Intractable Rare Dis Res. 2020;9(1):1\u20139.","journal-title":"Intractable Rare Dis Res"},{"key":"2285_CR3","doi-asserted-by":"crossref","first-page":"100874","DOI":"10.1016\/j.spen.2021.100874","volume":"37","author":"KL McBride","year":"2021","unstructured":"McBride KL, Flanigan KM. Update in the Mucopolysaccharidoses. Semin Pediatr Neurol. 2021;37:100874.","journal-title":"Semin Pediatr Neurol."},{"issue":"8249","key":"2285_CR4","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0140-6736(81)91046-1","volume":"2","author":"JR Hobbs","year":"1981","unstructured":"Hobbs JR, Hugh-Jones K, Barrett AJ, Byrom N, Chambers D, Henry K, et al. Reversal of clinical features of Hurler\u2019s disease and biochemical improvement after treatment by bone-marrow transplantation. Lancet. 1981;2(8249):709\u201312.","journal-title":"Lancet"},{"key":"2285_CR5","doi-asserted-by":"crossref","first-page":"100508","DOI":"10.1016\/j.ymgmr.2019.100508","volume":"21","author":"C Lampe","year":"2019","unstructured":"Lampe C, McNelly B, Gevorkian AK, Hendriksz CJ, Lobzhanidze TV, P\u00e9rez-L\u00f3pez J, et al. Transition of patients with mucopolysaccharidosis from paediatric to adult care. Mol Genet Metab Rep. 2019;21:100508.","journal-title":"Mol Genet Metab Rep."},{"key":"2285_CR6","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/0076-6879(82)83052-8","volume":"83","author":"H Kresse","year":"1982","unstructured":"Kresse H, von Figura K, Klein U, Gl\u00f6ssl J, Paschke E, Pohlmann R. Enzymic diagnosis of the genetic mucopolysaccharide storage disorders. Methods Enzymol. 1982;83:559\u201372.","journal-title":"Methods Enzymol"},{"issue":"6","key":"2285_CR7","doi-asserted-by":"crossref","first-page":"931","DOI":"10.2174\/138920111795542615","volume":"12","author":"S Tomatsu","year":"2011","unstructured":"Tomatsu S, Monta\u00f1o AM, Oikawa H, Smith M, Barrera L, Chinen Y, et al. Mucopolysaccharidosis type IVA (Morquio A disease): clinical review and current treatment. Curr Pharm Biotechnol. 2011;12(6):931\u201345.","journal-title":"Curr Pharm Biotechnol"},{"issue":"11","key":"2285_CR8","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1002\/humu.22635","volume":"35","author":"A Morrone","year":"2014","unstructured":"Morrone A, Caciotti A, Atwood R, Davidson K, Du C, Francis-Lyon P, et al. Morquio A syndrome-associated mutations: a review of alterations in the GALNS gene and a new locus-specific database. Hum Mutat. 2014;35(11):1271\u20139.","journal-title":"Hum Mutat"},{"issue":"1","key":"2285_CR9","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/ajmg.a.36833","volume":"167A","author":"CJ Hendriksz","year":"2015","unstructured":"Hendriksz CJ, Berger KI, Giugliani R, Harmatz P, Kampmann C, Mackenzie WG, et al. International guidelines for the management and treatment of Morquio A syndrome. Am J Med Genet A. 2015;167A(1):11\u201325.","journal-title":"Am J Med Genet A"},{"issue":"2","key":"2285_CR10","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s10545-007-0529-7","volume":"30","author":"AM Montano","year":"2007","unstructured":"Montano AM, Tomatsu S, Gottesman GS, Smith M, Orii T. International Morquio A Registry: clinical manifestation and natural course of Morquio A disease. J Inherit Metab Dis. 2007;30(2):165\u201374.","journal-title":"J Inherit Metab Dis"},{"key":"2285_CR11","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ymgme.2013.01.021","volume":"109","author":"P Harmatz","year":"2013","unstructured":"Harmatz P, Mengel KE, Giugliani R, Valayannopoulos V, Lin SP, Parini R, et al. The Morquio A clinical assessment program: baseline results illustrating progressive, multisystemic clinical impairments in Morquio A subjects. Mol Genet Metab. 2013;109:54\u201361.","journal-title":"Mol Genet Metab"},{"key":"2285_CR12","first-page":"59","volume":"15","author":"C Lavery","year":"2015","unstructured":"Lavery C, Hendriksz C. Mortality in patients with Morquio syndrome A. JIMD Rep. 2015;15:59\u201366.","journal-title":"JIMD Rep"},{"issue":"6","key":"2285_CR13","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1007\/s10545-014-9715-6","volume":"37","author":"CJ Hendriksz","year":"2014","unstructured":"Hendriksz CJ, Burton B, Fleming TR, Harmatz P, Hughes D, Jones SA, et al. Efficacy and safety of enzyme replacement therapy with BMN 110 (elosulfase alfa) for Morquio A syndrome (mucopolysaccharidosis IVA): a phase 3 randomised placebo-controlled study. J Inherit Metab Dis. 2014;37(6):979\u201390.","journal-title":"J Inherit Metab Dis"},{"issue":"12","key":"2285_CR14","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1080\/17512433.2017.1260000","volume":"9","author":"CJ Hendriksz","year":"2016","unstructured":"Hendriksz CJ. Elosulfase alfa (BMN 110) for the treatment of mucopolysaccharidosis IVA (Morquio A Syndrome). Expert Rev Clin Pharmacol. 2016;9(12):1521\u201332.","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"5","key":"2285_CR15","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s40259-014-0108-z","volume":"28","author":"KA Lyseng-Williamson","year":"2014","unstructured":"Lyseng-Williamson KA. Elosulfase Alfa: a review of its use in patients with mucopolysaccharidosis type IVA (Morquio A syndrome). BioDrugs. 2014;28(5):465\u201375.","journal-title":"BioDrugs"},{"issue":"1\u20132","key":"2285_CR16","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ymgme.2016.05.018","volume":"119","author":"CJ Hendriksz","year":"2016","unstructured":"Hendriksz CJ, Parini R, AlSayed MD, Raiman J, Giugliani R, Solano Villarreal ML, et al. Long-term endurance and safety of elosulfase alfa enzyme replacement therapy in patients with Morquio A syndrome. Mol Genet Metab. 2016;119(1\u20132):131\u201343.","journal-title":"Mol Genet Metab"},{"issue":"1","key":"2285_CR17","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s13023-021-01675-x","volume":"16","author":"M Cleary","year":"2021","unstructured":"Cleary M, Davison J, Gould R, Geberhiwot T, Hughes D, Mercer J, et al. Impact of long-term elosulfase alfa treatment on clinical and patient-reported outcomes in patients with mucopolysaccharidosis type IVA: results from a Managed Access Agreement in England. Orphanet J Rare Dis. 2021;16(1):38.","journal-title":"Orphanet J Rare Dis"},{"key":"2285_CR18","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s13023-017-0634-0","volume":"12","author":"D Hughes","year":"2017","unstructured":"Hughes D, Giugliani R, Guffon N, Jones SA, Mengel KE, Parini R, et al. Clinical outcomes in a subpopulation of adults with Morquio a syndrome: results from a long-term extension study of elosulfase alfa. Orphanet J Rare Dis. 2017;12:98.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"2285_CR19","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s13023-019-1074-9","volume":"14","author":"MU Akyol","year":"2019","unstructured":"Akyol MU, Alden TD, Amartino H, Ashworth J, Belani K, Berger KI, et al. Recommendations for the management of MPS IVA: systematic evidence- and consensus-based guidance. Orphanet J Rare Dis. 2019;14(1):137.","journal-title":"Orphanet J Rare Dis"},{"key":"2285_CR20","doi-asserted-by":"crossref","unstructured":"Lampe C, Dionisi-Vici C, Bellettato CM, Paneghetti L, van Lingen C, Bond S, et al. MetabERN collaboration group. The impact of COVID-19 on rare metabolic patients and healthcare providers: results from two MetabERN surveys. Orphanet J Rare Dis. 2020;15(1):341.","DOI":"10.1186\/s13023-020-01619-x"},{"issue":"2","key":"2285_CR21","first-page":"65","volume":"2012","author":"S Tomatsu","year":"2012","unstructured":"Tomatsu S, Mackenzie WG, Theroux MC, Mason RW, Thacker MM, Shaffer TH, et al. Current and emerging treatments and surgical interventions for Morquio A syndrome: a review. Res Rep Endocr Disord. 2012;2012(2):65\u201377.","journal-title":"Res Rep Endocr Disord"},{"issue":"4","key":"2285_CR22","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.3390\/ijms21041517","volume":"21","author":"K Sawamoto","year":"2020","unstructured":"Sawamoto K, \u00c1lvarez Gonz\u00e1lez JV, Piechnik M, Otero FJ, Couce ML, Suzuki Y, Tomatsu S. Mucopolysaccharidosis IVA: diagnosis, treatment, and management. Int J Mol Sci. 2020;21(4):1517.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"2285_CR23","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ymgme.2013.11.015","volume":"111","author":"J Muenzer","year":"2014","unstructured":"Muenzer J. Early initiation of enzyme replacement therapy for the mucopolysaccharidoses. Mol Genet Metab. 2014;111(2):63\u201372.","journal-title":"Mol Genet Metab"},{"issue":"Suppl 2","key":"2285_CR24","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s13052-018-0562-1","volume":"44","author":"D Concolino","year":"2018","unstructured":"Concolino D, Deodato F, Parini R. Enzyme replacement therapy: efficacy and limitations. Ital J Pediatr. 2018;44(Suppl 2):120.","journal-title":"Ital J Pediatr"},{"key":"2285_CR25","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1056\/NEJM199105233242104","volume":"324","author":"NW Barton","year":"1991","unstructured":"Barton NW, Brady RO, Dambrosia JM, Di Bisceglie AM, Doppelt SH, Hill SC, et al. Replacement therapy for inherited enzyme deficiency-macrophage-targeted glucocerebrosidase for Gaucher\u2019s disease. N Eng J Med. 1991;324:1464\u201370.","journal-title":"N Eng J Med"},{"key":"2285_CR26","unstructured":"Aldurazyme\u00ae, European public assessment report. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/aldurazyme. Accessed 1 Oct 2021."},{"key":"2285_CR27","unstructured":"Naglazyme\u00ae. European public assessment report. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/naglazyme. Accessed 1 Oct 2021."},{"key":"2285_CR28","unstructured":"Elaprase\u00ae, European public assessment report. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/elaprase. Accessed 1 Oct 2021."},{"key":"2285_CR29","unstructured":"MEPSEVII\u00ae, European public assessment report. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/mepsevii. Accessed 1 Oct 2021."},{"issue":"8","key":"2285_CR30","doi-asserted-by":"crossref","first-page":"2975","DOI":"10.3390\/ijms21082975","volume":"21","author":"R Parini","year":"2020","unstructured":"Parini R, Deodato F. Intravenous enzyme replacement therapy in Mucopolysaccharidoses: clinical effectiveness and limitations. Int J Mol Sci. 2020;21(8):2975.","journal-title":"Int J Mol Sci"},{"key":"2285_CR31","doi-asserted-by":"crossref","unstructured":"Heard JM, Vrinten C, Schlander M, Bellettato CM, van Lingen C, Scarpa M; MetabERN collaboration group. Availability, accessibility and delivery to patients of the 28 orphan medicines approved by the European Medicine Agency for hereditary metabolic diseases in the MetabERN network. Orphanet J Rare Dis. 2020;15(1):3.","DOI":"10.1186\/s13023-019-1280-5"},{"key":"2285_CR32","first-page":"652","volume":"8","author":"KM Stepien","year":"2021","unstructured":"Stepien KM, Kie\u0107-Wilk B, Lampe C, Tangeraas T, Cefalo G, Belmatoug N, et al. Challenges in transition from childhood to adulthood care in rare metabolic diseases: results from the first multi-center European Survey. Front Med (Lausanne). 2021;8:652.","journal-title":"Front Med (Lausanne)."},{"issue":"1","key":"2285_CR33","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1186\/s13023-021-01880-8","volume":"16","author":"Y Puckett","year":"2021","unstructured":"Puckett Y, Mallorga-Hern\u00e1ndez A, Monta\u00f1o AM. Epidemiology of mucopolysaccharidoses (MPS) in United States: challenges and opportunities. Orphanet J Rare Dis. 2021;16(1):241.","journal-title":"Orphanet J Rare Dis"},{"issue":"11","key":"2285_CR34","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1111\/j.1651-2227.2008.00965.x","volume":"97","author":"G Malm","year":"2008","unstructured":"Malm G, Lund AM, M\u00e5nsson JE, Heiberg A. Mucopolysaccharidoses in the Scandinavian countries: incidence and prevalence. Acta Paediatr. 2008;97(11):1577\u201381.","journal-title":"Acta Paediatr"},{"issue":"10149","key":"2285_CR35","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/S0140-6736(18)31069-9","volume":"392","author":"L Luzzatto","year":"2018","unstructured":"Luzzatto L, Hyry HI, Schieppati A, Costa E, Simoens S, Schaefer F, et al. Outrageous prices of orphan drugs: a call for collaboration. Lancet. 2018;392(10149):791\u20134.","journal-title":"Lancet"},{"key":"2285_CR36","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.ejim.2016.05.017","volume":"34","author":"J Mitchell","year":"2016","unstructured":"Mitchell J, Berger KI, Borgo A, Braunlin EA, Burton BK, Ghotme KA, et al. Unique medical issues in adult patients with mucopolysaccharidoses. Eur J Intern Med. 2016;34:2\u201310.","journal-title":"Eur J Intern Med"},{"issue":"1","key":"2285_CR37","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1186\/s13023-020-01382-z","volume":"15","author":"KM Stepien","year":"2020","unstructured":"Stepien KM, Gevorkyan AK, Hendriksz CJ, Lobzhanidze TV, P\u00e9rez-L\u00f3pez J, Tol G, et al. Critical clinical situations in adult patients with Mucopolysaccharidoses (MPS). Orphanet J Rare Dis. 2020;15(1):114.","journal-title":"Orphanet J Rare Dis"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-022-02285-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-022-02285-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-022-02285-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,25]],"date-time":"2022-03-25T07:58:51Z","timestamp":1648195131000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-022-02285-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,24]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2285"],"URL":"https:\/\/doi.org\/10.1186\/s13023-022-02285-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-1071210\/v1","asserted-by":"object"}]},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,24]]},"assertion":[{"value":"15 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Z. Almassyzs, V. Christophidou-Anastasiadou, I. Barisic, R. \u010cerkauskien\u0117, M Djordjevic, A. Hlavata, B. Kiec-Wilk, V. Plaiasu, M. Samardzic have no competing interests to declare. D. Avdjieva-Tzavella has received speaker honoraria, travel and accommodation funding from Takeda and Sanofi Genzyme. G. Cuturilo has received speaker honoraria and\/or travel grants from BioMarin, Takeda and Sanofi Genzyme. Z. Gucev has received speaker and advisory board honoraria from Novo Nordisk, Merck, and Takeda. C. Lampe has received advisory board and speaker honoraria, travel expenses and consultancy honoraria from Sanofi, BioMarin, Amicus, Alexion, Takeda, Chiesi, Regenxbio. M. Magner has received speaker honoraria from BioMarin and Takeda and consultancy fees from BioMarin and Chiesi. I. Pecin has received advisory board and speaker honoraria from Sanofi, Sandoz, Genzyme, Takeda, Amicus. A. Tylki-Sziymanska has received speaker honoraria and\/or travel grants from BioMarin, Sanofi Genzyme, Alexion, Chiesi, and Shire\/Takeda. D. Zafeiriou has received honoraria, travel and research grants from Sanofi-Genzyme, Takeda, BioMarin, Novartis, Biogen and UCB. I. Zaganas has received consultancy honoraria from Akcea, Alnylam, BioMarin, Genesis Pharma, Roche, Specifar\/Teva.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"136"}}